These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 10086547)
1. Induction immunosuppression for lung transplantation with OKT3. Wain JC; Wright CD; Ryan DP; Zorb SL; Mathisen DJ; Ginns LC Ann Thorac Surg; 1999 Jan; 67(1):187-93. PubMed ID: 10086547 [TBL] [Abstract][Full Text] [Related]
2. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials. Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362 [TBL] [Abstract][Full Text] [Related]
3. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis. Barlow CW; Moon MR; Green GR; Gamberg P; Theodore J; Reitz BA; Robbins RC Transpl Int; 2001 Aug; 14(4):234-9. PubMed ID: 11512056 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3. Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282 [TBL] [Abstract][Full Text] [Related]
6. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608 [TBL] [Abstract][Full Text] [Related]
7. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Wilde MI; Goa KL Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551 [TBL] [Abstract][Full Text] [Related]
8. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643 [TBL] [Abstract][Full Text] [Related]
9. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3. Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. Shennib H; Massard G; Reynaud M; Noirclerc M J Heart Lung Transplant; 1994; 13(3):514-9. PubMed ID: 8061029 [TBL] [Abstract][Full Text] [Related]
11. Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation. Wall WJ; Ghent CN; Roy A; McAlister VC; Grant DR; Adams PC Dig Dis Sci; 1995 Jan; 40(1):52-7. PubMed ID: 7821119 [TBL] [Abstract][Full Text] [Related]
12. The impact of cytolytic therapy on bronchiolitis obliterans syndrome. Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858 [TBL] [Abstract][Full Text] [Related]
14. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187 [TBL] [Abstract][Full Text] [Related]
15. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721 [TBL] [Abstract][Full Text] [Related]
16. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M; Latter DA; Loertscher R Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721 [TBL] [Abstract][Full Text] [Related]
17. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Vallhonrat H; Williams WW; Cosimi AB; Tolkoff-Rubin N; Ginns LC; Wain JC; Preffer F; Olszak I; Wee S; Delmonico FL; Pascual M Transplantation; 1999 Jan; 67(2):253-8. PubMed ID: 10075589 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic OKT3 used as induction therapy for heart transplantation. Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108 [TBL] [Abstract][Full Text] [Related]